The Tough Tech problem we are solving
Antibody-based therapeutics are among the most promising tools for treating cancer today, but they are limited by the small number of viable targets. Out of more than 200 types of cancer, fewer than 20 targets have approved antibody therapeutics. This gap highlights a pressing need for new target discovery.
About our solution
With our focus on harnessing the power of AI and machine learning, we are crafting an innovative atlas of antibody targets on the surface of cancer cells. This sets the stage for groundbreaking discoveries of new cancer targets and the development of improved therapeutics. At TenSixty, we're not just chasing after new targets; we're on a mission to create transformative drugs that will save lives and redefine oncology.